$VCEL
Vericel Corp

2014 Q3 Form 10-Q Financial Statement

#000110465914060912 Filed on August 14, 2014

View on sec.gov

Income Statement

Concept 2014 Q3 2014 Q2 2013 Q4
Revenue $9.658M $4.432M $10.00K
YoY Change 147633.33% -47.37%
Cost Of Revenue $5.532M $5.009M $0.00
YoY Change 500800.0%
Gross Profit $4.126M -$577.0K $10.00K
YoY Change -28950.0% -50.0%
Gross Profit Margin 42.72% -13.02% 100.0%
Selling, General & Admin $4.313M $3.581M $1.620M
YoY Change 304.6% 129.55% 0.0%
% of Gross Profit 104.53% 16200.0%
Research & Development $7.835M $4.364M $3.320M
YoY Change 204.27% 18.72% -44.76%
% of Gross Profit 189.89% 33200.0%
Depreciation & Amortization $200.0K $100.0K $100.0K
YoY Change 81.82% -23.08% -37.5%
% of Gross Profit 4.85% 1000.0%
Operating Expenses $12.15M $7.945M $4.930M
YoY Change 233.64% 51.74% -35.47%
Operating Profit -$8.022M -$8.522M -$4.920M
YoY Change 120.32% 62.82% -35.41%
Interest Expense $1.000K $2.000K $2.010M
YoY Change -66.67% -33.33% 107.22%
% of Operating Profit
Other Income/Expense, Net $1.105M $3.884M
YoY Change -19.23% 1025.8%
Pretax Income -$6.920M -$4.640M -$2.920M
YoY Change 204.85% -5.11% -56.09%
Income Tax $0.00
% Of Pretax Income
Net Earnings -$6.917M -$4.638M -$2.920M
YoY Change 204.31% -5.13% -56.09%
Net Earnings / Revenue -71.62% -104.65% -29200.0%
Basic Earnings Per Share
Diluted Earnings Per Share -$673.8K -$711.7K -$650.3K
COMMON SHARES
Basic Shares Outstanding 8.001M shares 6.497M shares 4.380M shares
Diluted Shares Outstanding

Balance Sheet

Concept 2014 Q3 2014 Q2 2013 Q4
SHORT-TERM ASSETS
Cash & Short-Term Investments $37.60M $7.300M $8.100M
YoY Change 248.15% 62.22% -40.44%
Cash & Equivalents $37.60M $7.300M $8.059M
Short-Term Investments
Other Short-Term Assets $1.500M $610.0K $409.0K
YoY Change 175.23% 158.47% 16.19%
Inventory $1.700M $1.922M $0.00
Prepaid Expenses
Receivables $4.000M $4.317M $8.000K
Other Receivables $0.00 $0.00 $0.00
Total Short-Term Assets $44.70M $14.11M $8.476M
YoY Change 293.45% 198.35% -39.41%
LONG-TERM ASSETS
Property, Plant & Equipment $2.400M $2.387M $739.0K
YoY Change 185.37% 150.47% -37.79%
Goodwill
YoY Change
Intangibles $3.337M
YoY Change
Long-Term Investments
YoY Change
Other Assets
YoY Change
Total Long-Term Assets $5.700M $5.724M $739.0K
YoY Change 577.76% 500.63% -37.79%
TOTAL ASSETS
Total Short-Term Assets $44.70M $14.11M $8.476M
Total Long-Term Assets $5.700M $5.724M $739.0K
Total Assets $50.40M $19.84M $9.215M
YoY Change 313.05% 249.04% -39.29%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $2.500M $2.909M $2.355M
YoY Change -13.79% -11.85% -17.16%
Accrued Expenses $3.100M $2.505M $294.0K
YoY Change 933.33% 401.0% -27.23%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $2.500M $6.000K
YoY Change
Long-Term Debt Due $0.00 $6.000K
YoY Change -100.0% -82.35%
Total Short-Term Liabilities $12.50M $17.05M $5.321M
YoY Change 72.37% 343.81% -5.97%
LONG-TERM LIABILITIES
Long-Term Debt $100.0K $0.00 $0.00
YoY Change -100.0%
Other Long-Term Liabilities
YoY Change
Total Long-Term Liabilities $100.0K $0.00 $0.00
YoY Change -100.0%
TOTAL LIABILITIES
Total Short-Term Liabilities $12.50M $17.05M $5.321M
Total Long-Term Liabilities $100.0K $0.00 $0.00
Total Liabilities $12.60M $17.10M $5.321M
YoY Change 73.75% 345.08% -6.07%
SHAREHOLDERS EQUITY
Retained Earnings -$287.8M
YoY Change 4.52%
Common Stock $253.3M
YoY Change 4.13%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $37.80M $2.785M $3.894M
YoY Change
Total Liabilities & Shareholders Equity $50.40M $19.84M $9.215M
YoY Change 313.05% 249.04% -39.29%

Cashflow Statement

Concept 2014 Q3 2014 Q2 2013 Q4
OPERATING ACTIVITIES
Net Income -$6.917M -$4.638M -$2.920M
YoY Change 204.31% -5.13% -56.09%
Depreciation, Depletion And Amortization $200.0K $100.0K $100.0K
YoY Change 81.82% -23.08% -37.5%
Cash From Operating Activities -$8.430M -$6.070M -$4.340M
YoY Change 103.62% 29.15% -40.87%
INVESTING ACTIVITIES
Capital Expenditures -$70.00K -$10.00K $0.00
YoY Change -50.0% -100.0%
Acquisitions
YoY Change
Other Investing Activities -$2.500M $1.050M $0.00
YoY Change
Cash From Investing Activities -$2.570M $1.040M $0.00
YoY Change -5300.0% -100.0%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net $37.50M
YoY Change 357.32%
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 41.32M 3.460M 1.580M
YoY Change 295.03% -34700.0% -15900.0%
NET CHANGE
Cash From Operating Activities -8.430M -6.070M -4.340M
Cash From Investing Activities -2.570M 1.040M 0.000
Cash From Financing Activities 41.32M 3.460M 1.580M
Net Change In Cash 30.32M -1.570M -2.760M
YoY Change 379.75% -66.81% -62.95%
FREE CASH FLOW
Cash From Operating Activities -$8.430M -$6.070M -$4.340M
Capital Expenditures -$70.00K -$10.00K $0.00
Free Cash Flow -$8.360M -$6.060M -$4.340M
YoY Change 101.93% 29.49% -40.06%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2014Q2 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
3884000 USD
CY2013Q2 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
345000 USD
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
2533000 USD
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
1966000 USD
us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
246000 USD
us-gaap Share Based Compensation
ShareBasedCompensation
451000 USD
us-gaap Business Combination Bargain Purchase Gain Recognized Amount
BusinessCombinationBargainPurchaseGainRecognizedAmount
3634000 USD
us-gaap Foreign Currency Transaction Gain Loss Unrealized
ForeignCurrencyTransactionGainLossUnrealized
-5000 USD
us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
275000 USD
us-gaap Share Based Compensation
ShareBasedCompensation
383000 USD
us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
-278000 USD
us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
4594000 USD
CY2013Q2 us-gaap Net Income Loss
NetIncomeLoss
-4889000 USD
us-gaap Net Income Loss
NetIncomeLoss
-10633000 USD
us-gaap Net Income Loss
NetIncomeLoss
-10433000 USD
CY2014Q2 us-gaap Preferred Stock Dividends Income Statement Impact
PreferredStockDividendsIncomeStatementImpact
1474000 USD
us-gaap Preferred Stock Dividends Income Statement Impact
PreferredStockDividendsIncomeStatementImpact
2892000 USD
us-gaap Preferred Stock Dividends Income Statement Impact
PreferredStockDividendsIncomeStatementImpact
2577000 USD
CY2014Q2 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-6112000 USD
CY2013Q2 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-6203000 USD
us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-13525000 USD
us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-13010000 USD
CY2014Q2 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
6518000 shares
CY2013Q2 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
2283000 shares
us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
6195000 shares
us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
2263000 shares
CY2014Q2 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.94
CY2013Q2 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-2.72
us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-2.18
us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-5.75
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
2639000 shares
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
1320000 shares
CY2014Q2 us-gaap Accounts Payable Current
AccountsPayableCurrent
2909000 USD
CY2013Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
2355000 USD
CY2014Q2 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
2505000 USD
CY2013Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
294000 USD
us-gaap Payments To Acquire Businesses Net Of Cash Acquired
PaymentsToAcquireBusinessesNetOfCashAcquired
-1050000 USD
us-gaap Business Combination Consideration Transferred Liabilities Incurred
BusinessCombinationConsiderationTransferredLiabilitiesIncurred
2500000 USD
CY2014Q2 us-gaap Restructuring Reserve Current
RestructuringReserveCurrent
2605000 USD
CY2014Q2 us-gaap Asset Retirement Obligation Current
AssetRetirementObligationCurrent
1600000 USD
CY2014Q2 us-gaap Accounts Payable And Other Accrued Liabilities Current
AccountsPayableAndOtherAccruedLiabilitiesCurrent
226000 USD
CY2013Q4 us-gaap Accounts Payable And Other Accrued Liabilities Current
AccountsPayableAndOtherAccruedLiabilitiesCurrent
27000 USD
CY2014Q2 us-gaap Accounts Payable And Accrued Liabilities Current
AccountsPayableAndAccruedLiabilitiesCurrent
9845000 USD
CY2013Q4 us-gaap Accounts Payable And Accrued Liabilities Current
AccountsPayableAndAccruedLiabilitiesCurrent
2676000 USD
CY2013Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
15000000 shares
CY2013Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
4723000 shares
CY2013Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
4723000 shares
CY2014Q2 us-gaap Common Stock No Par Value
CommonStockNoParValue
CY2014Q2 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
75000000 shares
CY2014Q2 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
7019000 shares
CY2014Q2 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
7019000 shares
dei Entity Registrant Name
EntityRegistrantName
AASTROM BIOSCIENCES INC
dei Entity Central Index Key
EntityCentralIndexKey
0000887359
dei Document Type
DocumentType
10-Q
dei Document Period End Date
DocumentPeriodEndDate
2014-06-30
dei Amendment Flag
AmendmentFlag
false
dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
dei Entity Filer Category
EntityFilerCategory
Smaller Reporting Company
CY2014Q3 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
8001340 shares
dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2014
dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q2
CY2013Q2 us-gaap Interest Expense
InterestExpense
3000 USD
us-gaap Increase Decrease In Receivables
IncreaseDecreaseInReceivables
-24000 USD
CY2013Q2 us-gaap Investment Income Interest
InvestmentIncomeInterest
3000 USD
us-gaap Investment Income Interest
InvestmentIncomeInterest
6000 USD
us-gaap Investment Income Interest
InvestmentIncomeInterest
8000 USD
us-gaap Interest Expense
InterestExpense
6000 USD
us-gaap Basis Of Accounting
BasisOfAccounting
<div style="font-size:10.0pt;font-family:Times New Roman;"> <p style="MARGIN: 0in 0in 0pt;"><b><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold;" size="2">NOTE 3 &#8212; BASIS OF PRESENTATION:</font></b></p> <p style="MARGIN: 0in 0in 0pt;">&#160;</p> <p style="TEXT-ALIGN: justify; MARGIN: 0in 0in 0pt;"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">The condensed consolidated financial statements included herein have been prepared in accordance with the rules&#160;and regulations of the U.S. Securities and Exchange Commission (SEC).&#160;</font> <font style="FONT-SIZE: 10pt;" size="2">The preparation of condensed consolidated financial statements in conformity with generally accepted accounting principles in the United States of America (U.S. GAAP) requires management to make estimates, judgments, and assumptions that may affect the reported amounts of assets, liabilities, equity, revenues and expenses.</font> <font style="FONT-SIZE: 10pt;" size="2">Certain information and footnote disclosures normally included in financial statements prepared in accordance with U.S. GAAP have been omitted pursuant to such rules&#160;and regulations. The financial statements reflect, in the opinion of management, all adjustments (consisting only of normal, recurring adjustments) necessary to state fairly the financial position and results of operations as of and for the periods indicated.&#160; The results of operations for the six months ended June&#160;30, 2014, are not necessarily indicative of the results to be expected for the full year or for any other period.&#160; The December&#160;31, 2013 condensed consolidated balance sheet data was derived from the Company&#8217;s audited consolidated financial statements, but does not include all disclosures required by U.S. GAAP.</font></p> <p style="MARGIN: 0in 0in 0pt;">&#160;</p> <p style="TEXT-ALIGN: justify; MARGIN: 0in 0in 0pt;"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">These condensed consolidated financial statements should be read in conjunction with the audited consolidated financial statements and the notes thereto included in our Annual Report on Form&#160;10-K for the period ended December&#160;31, 2013, as filed with the SEC on March 13, 2014 (Annual Report).</font></p> <p style="MARGIN: 0in 0in 0pt;">&#160;</p> <p style="TEXT-ALIGN: justify; MARGIN: 0in 0in 0pt;"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">The consolidated financial statements include the accounts of Aastrom and its wholly-owned subsidiaries, Aastrom Biosciences GmbH, located in Berlin, Germany, Marrow Donation, LLC, located in San Diego, California, and Aastrom Biosciences DK ApS, in Kastrup, Demark (collectively, the Company).&#160; All inter-company transactions and accounts have been eliminated in consolidation.&#160; Aastrom Biosciences GmbH has ceased operations.</font></p> </div>
CY2014Q2 us-gaap Net Income Loss
NetIncomeLoss
-4638000 USD
CY2013Q2 us-gaap Preferred Stock Dividends Income Statement Impact
PreferredStockDividendsIncomeStatementImpact
1314000 USD
us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
1104000 USD
CY2013Q4 us-gaap Warrants And Rights Outstanding
WarrantsAndRightsOutstanding
2019000 USD
CY2014Q2 us-gaap Warrants And Rights Outstanding
WarrantsAndRightsOutstanding
2974000 USD
astm Class Of Warrant Or Right Warrants Exercised Value
ClassOfWarrantOrRightWarrantsExercisedValue
149000 USD
CY2014Q2 us-gaap Finite Lived Intangible Assets Net
FiniteLivedIntangibleAssetsNet
3360000 USD
CY2014Q2 us-gaap Short Term Borrowings
ShortTermBorrowings
2500000 USD
us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
5300000 USD
us-gaap Number Of Reportable Segments
NumberOfReportableSegments
1 item
CY2014Q2 us-gaap Cash
Cash
7263000 USD
astm Maximum Period Before Cash And Cash Equivalents Are Fully Depleted
MaximumPeriodBeforeCashAndCashEquivalentsAreFullyDepleted
P1Y
astm Minimum Period Of Uncertainty Regarding Entitys Ability To Maintain Liquidity Sufficient To Operate Business Effectively
MinimumPeriodOfUncertaintyRegardingEntitysAbilityToMaintainLiquiditySufficientToOperateBusinessEffectively
P12M
CY2014Q2 us-gaap Restructuring And Related Cost Number Of Positions Eliminated Inception To Date
RestructuringAndRelatedCostNumberOfPositionsEliminatedInceptionToDate
80 item
CY2014Q2 us-gaap Restructuring And Related Cost Number Of Positions Eliminated Inception To Date Percent
RestructuringAndRelatedCostNumberOfPositionsEliminatedInceptionToDatePercent
0.30 pure
CY2014Q2 us-gaap Restructuring Charges
RestructuringCharges
3000000 USD
CY2014Q2 us-gaap Restructuring Reserve
RestructuringReserve
2600000 USD
CY2014Q2 us-gaap Restructuring And Related Cost Expected Cost
RestructuringAndRelatedCostExpectedCost
600000 USD
CY2014Q2 astm Restructuring And Related Cost Expected Stay On Bonus Cost
RestructuringAndRelatedCostExpectedStayOnBonusCost
200000 USD
CY2014Q2 us-gaap Asset Retirement Obligation
AssetRetirementObligation
1600000 USD
CY2014Q2 us-gaap Inventory Raw Materials
InventoryRawMaterials
867000 USD
CY2014Q2 us-gaap Inventory Work In Process
InventoryWorkInProcess
582000 USD
CY2014Q2 us-gaap Inventory Finished Goods
InventoryFinishedGoods
473000 USD
CY2014Q2 us-gaap Inventory Net
InventoryNet
1922000 USD
CY2014Q2 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
4308000 USD
CY2014Q2 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
6695000 USD
CY2013Q4 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
4825000 USD
CY2013Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
4086000 USD
CY2014Q2 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
2387000 USD
CY2013Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
739000 USD
CY2014Q2 us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
20000 USD
us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
0 USD
CY2014Q2 us-gaap Finite Lived Intangible Assets Amortization Expense Next Rolling Twelve Months
FiniteLivedIntangibleAssetsAmortizationExpenseNextRollingTwelveMonths
163000 USD
us-gaap Operating Leases Rent Expense Net
OperatingLeasesRentExpenseNet
500000 USD
CY2014Q2 us-gaap Finite Lived Intangible Assets Amortization Expense Rolling Year Two
FiniteLivedIntangibleAssetsAmortizationExpenseRollingYearTwo
280000 USD
CY2014Q2 us-gaap Finite Lived Intangible Assets Amortization Expense Rolling Year Three
FiniteLivedIntangibleAssetsAmortizationExpenseRollingYearThree
280000 USD
CY2014Q2 us-gaap Finite Lived Intangible Assets Amortization Expense Rolling Year Four
FiniteLivedIntangibleAssetsAmortizationExpenseRollingYearFour
280000 USD
CY2014Q2 us-gaap Finite Lived Intangible Assets Amortization Expense Rolling Year Five
FiniteLivedIntangibleAssetsAmortizationExpenseRollingYearFive
280000 USD
CY2014Q2 us-gaap Finite Lived Intangible Assets Amortization Expense Rolling After Year Five
FiniteLivedIntangibleAssetsAmortizationExpenseRollingAfterYearFive
2077000 USD
CY2013 astm Operating Lease Term
OperatingLeaseTerm
P5Y
CY2013 astm Operating Lease Number Of Five Year Market Value Renewals
OperatingLeaseNumberOfFiveYearMarketValueRenewals
2 item
CY2013 astm Operating Lease Period Of Market Value Renewals
OperatingLeasePeriodOfMarketValueRenewals
P5Y
CY2013 astm Operating Lease Rating Class Of Modular Manufacturing Clean Room Laboratories And Office Space Leased
OperatingLeaseRatingClassOfModularManufacturingCleanRoomLaboratoriesAndOfficeSpaceLeased
100000 item
CY2014Q2 us-gaap Business Combination Contingent Consideration Arrangements Range Of Outcomes Value High
BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueHigh
15800000 USD
CY2014Q2 astm Operating Leases Sales Force Leased Auto Fleet Future Minimum Payments Remainder Of Fiscal Year
OperatingLeasesSalesForceLeasedAutoFleetFutureMinimumPaymentsRemainderOfFiscalYear
97000 USD
CY2014Q2 astm Operating Leases Sales Force Leased Auto Fleet Payments Future Minimum Payments Due In Two Years
OperatingLeasesSalesForceLeasedAutoFleetPaymentsFutureMinimumPaymentsDueInTwoYears
194000 USD
CY2014Q2 astm Operating Leases Sales Force Leased Auto Fleet Payments Future Minimum Payments Due In Three Years
OperatingLeasesSalesForceLeasedAutoFleetPaymentsFutureMinimumPaymentsDueInThreeYears
166000 USD
CY2014Q2 astm Operating Leases Sales Force Leased Auto Fleet Payments Future Minimum Payments Due In Four Years
OperatingLeasesSalesForceLeasedAutoFleetPaymentsFutureMinimumPaymentsDueInFourYears
57000 USD
CY2014Q2 astm Operating Leases Sales Force Leased Auto Fleet Payments Future Minimum Payments Due In Five Years
OperatingLeasesSalesForceLeasedAutoFleetPaymentsFutureMinimumPaymentsDueInFiveYears
5000 USD
CY2014Q2 astm Operating Leases Sales Force Leased Auto Fleet Payments Future Minimum Payments Due
OperatingLeasesSalesForceLeasedAutoFleetPaymentsFutureMinimumPaymentsDue
519000 USD
CY2014Q2 us-gaap Operating Leases Future Minimum Payments Remainder Of Fiscal Year
OperatingLeasesFutureMinimumPaymentsRemainderOfFiscalYear
1881000 USD
CY2014Q2 us-gaap Operating Leases Future Minimum Payments Due In Two Years
OperatingLeasesFutureMinimumPaymentsDueInTwoYears
4282000 USD
CY2014Q2 us-gaap Operating Leases Future Minimum Payments Due In Three Years
OperatingLeasesFutureMinimumPaymentsDueInThreeYears
4222000 USD
CY2014Q2 us-gaap Operating Leases Future Minimum Payments Due In Four Years
OperatingLeasesFutureMinimumPaymentsDueInFourYears
1253000 USD
CY2014Q2 us-gaap Operating Leases Future Minimum Payments Due In Five Years
OperatingLeasesFutureMinimumPaymentsDueInFiveYears
338000 USD
CY2014Q2 us-gaap Operating Leases Future Minimum Payments Due
OperatingLeasesFutureMinimumPaymentsDue
11976000 USD
CY2013Q4 us-gaap Cash
Cash
8059000 USD
CY2014Q2 us-gaap Intangible Assets Net Excluding Goodwill
IntangibleAssetsNetExcludingGoodwill
3337000 USD
CY2013Q4 us-gaap Other Assets Current
OtherAssetsCurrent
409000 USD
CY2013Q4 us-gaap Assets Current
AssetsCurrent
8476000 USD
CY2013Q4 us-gaap Assets
Assets
9215000 USD
CY2013Q4 us-gaap Short Term Borrowings
ShortTermBorrowings
6000 USD
CY2014Q2 us-gaap Other Assets Current
OtherAssetsCurrent
610000 USD
CY2014Q2 us-gaap Assets Current
AssetsCurrent
14112000 USD
CY2014Q2 us-gaap Assets
Assets
19836000 USD
CY2014Q2 us-gaap Accrued Employee Benefits Current
AccruedEmployeeBenefitsCurrent
1732000 USD
CY2013Q4 us-gaap Accrued Employee Benefits Current
AccruedEmployeeBenefitsCurrent
620000 USD
CY2013Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
USD
CY2014Q2 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
USD
CY2014Q2 us-gaap Liabilities Current
LiabilitiesCurrent
17051000 USD
CY2013Q4 us-gaap Liabilities Current
LiabilitiesCurrent
5321000 USD
CY2014Q2 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
19836000 USD
CY2013Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
9215000 USD
CY2014Q2 us-gaap Stockholders Equity
StockholdersEquity
2785000 USD
CY2013Q4 us-gaap Stockholders Equity
StockholdersEquity
3894000 USD
CY2014Q2 us-gaap Development Stage Enterprise Deficit Accumulated During Development Stage
DevelopmentStageEnterpriseDeficitAccumulatedDuringDevelopmentStage
298398000 USD
CY2013Q4 us-gaap Development Stage Enterprise Deficit Accumulated During Development Stage
DevelopmentStageEnterpriseDeficitAccumulatedDuringDevelopmentStage
287765000 USD
CY2013Q4 us-gaap Common Stock Value
CommonStockValue
253270000 USD
CY2014Q2 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
5000 USD
CY2013Q4 us-gaap Common Stock No Par Value
CommonStockNoParValue
us-gaap Nature Of Operations
NatureOfOperations
<div style="font-size:10.0pt;font-family:Times New Roman;"> <p style="MARGIN: 0in 0in 0pt;"><b><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold;" size="2">NOTE 1&#8212; ORGANIZATION:</font></b></p> <p style="MARGIN: 0in 0in 0pt;">&#160;</p> <p style="MARGIN: 0in 0in 0pt; TEXT-AUTOSPACE:;"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">Aastrom Biosciences,&#160;Inc. (the Company or Aastrom) was incorporated in March&#160;1989 and began employee-based operations in 1991. On May&#160;30, 2014, Aastrom completed its acquisition of certain assets of Sanofi, a French soci&#233;t&#233; anonyme (Sanofi), including all of the outstanding equity interests of Genzyme Biosurgery ApS (</font><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">Genzyme Denmark)</font><font style="FONT-SIZE: 10pt;" size="2">, a wholly-owned subsidiary of Sanofi, and over 250 patents and patent applications and assumed certain liabilities for purposes of acquiring the portions of the cell therapy and regenerative medicine business (the CTRM Business). The CTRM Business researches, develops, manufactures, markets and sells the Carticel</font><font style="POSITION: relative; FONT-SIZE: 6.5pt; TOP: -3pt;" size="1">&#174;</font><font style="FONT-SIZE: 10pt;" size="2">, MACI</font><font style="POSITION: relative; FONT-SIZE: 6.5pt; TOP: -3pt;" size="1">TM</font><font style="FONT-SIZE: 10pt;" size="2">&#160;and Epicel</font><font style="POSITION: relative; FONT-SIZE: 6.5pt; TOP: -3pt;" size="1">&#174;</font><font style="FONT-SIZE: 10pt;" size="2">&#160;&#160;products. As a result, the Company has exited the development stage, and is now a fully integrated, commercial-stage biopharmaceutical company dedicated to the identification, development and commercialization of innovative therapies that enable the body to repair and regenerate damaged tissues and organs to restore normal structure and function.&#160; Aastrom has marketed products as well as developmental stage product candidates and the Company&#8217;s goal is to become the leader in cell therapy and regenerative medicine by developing, manufacturing and marketing best-in-class therapies for patients with significant unmet medical needs.</font></p> <p style="MARGIN: 0in 0in 0pt;">&#160;</p> <p style="TEXT-ALIGN: justify; MARGIN: 0in 0in 0pt;"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">The Company operates its business in one reportable segment &#8212; the research, product development, manufacture and distribution of patient-specific, expanded cellular therapies for use in the treatment of specific diseases.</font></p> <p style="TEXT-ALIGN: justify; MARGIN: 0in 0in 0pt;">&#160;</p> <p style="TEXT-ALIGN: justify; MARGIN: 0in 0in 0pt;"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">Successful future operations are subject to several technical hurdles and risk factors, including satisfactory product development, timely initiation and completion of clinical trials, regulatory approval and market acceptance of the Company&#8217;s products, successful integration and profitability of the CTRM Business and the Company&#8217;s continued ability to obtain future funding.</font></p> </div>
CY2014Q2 us-gaap Sales Revenue Goods Net
SalesRevenueGoodsNet
4432000 USD
CY2013Q2 us-gaap Sales Revenue Goods Net
SalesRevenueGoodsNet
3000 USD
us-gaap Sales Revenue Goods Net
SalesRevenueGoodsNet
4432000 USD
us-gaap Sales Revenue Goods Net
SalesRevenueGoodsNet
11000 USD
CY2014Q2 us-gaap Sales Revenue Net
SalesRevenueNet
4432000 USD
CY2013Q2 us-gaap Sales Revenue Net
SalesRevenueNet
3000 USD
us-gaap Sales Revenue Net
SalesRevenueNet
4432000 USD
us-gaap Sales Revenue Net
SalesRevenueNet
11000 USD
CY2012Q4 us-gaap Cash
Cash
13638000 USD
CY2013Q2 us-gaap Cash
Cash
4494000 USD
CY2014Q2 us-gaap Cost Of Goods Sold
CostOfGoodsSold
5009000 USD
CY2013Q2 us-gaap Cost Of Goods Sold
CostOfGoodsSold
1000 USD
us-gaap Cost Of Goods Sold
CostOfGoodsSold
5009000 USD
us-gaap Cost Of Goods Sold
CostOfGoodsSold
3000 USD
CY2014Q2 us-gaap Gross Profit
GrossProfit
-577000 USD
CY2013Q2 us-gaap Gross Profit
GrossProfit
2000 USD
us-gaap Gross Profit
GrossProfit
-577000 USD
us-gaap Gross Profit
GrossProfit
8000 USD
CY2014Q2 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
4364000 USD
CY2013Q2 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
3676000 USD
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
7635000 USD
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
9214000 USD
us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
3193000 USD
us-gaap Operating Expenses
OperatingExpenses
12407000 USD
us-gaap Operating Income Loss
OperatingIncomeLoss
-12399000 USD
CY2014Q2 us-gaap Operating Income Loss
OperatingIncomeLoss
-8522000 USD
CY2013Q2 us-gaap Operating Income Loss
OperatingIncomeLoss
-5234000 USD
us-gaap Operating Income Loss
OperatingIncomeLoss
-13166000 USD
us-gaap Operating Expenses
OperatingExpenses
12589000 USD
us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
4954000 USD
CY2014Q2 us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
3581000 USD
CY2014Q2 us-gaap Operating Expenses
OperatingExpenses
7945000 USD
CY2013Q2 us-gaap Operating Expenses
OperatingExpenses
5236000 USD
CY2013Q2 us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
1560000 USD
CY2014Q2 us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
-248000 USD
CY2013Q2 us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
-345000 USD
us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
-1964000 USD
us-gaap Increase Decrease In Receivables
IncreaseDecreaseInReceivables
4256000 USD
CY2014Q2 us-gaap Investment Income Interest
InvestmentIncomeInterest
4000 USD
CY2014Q2 us-gaap Interest Expense
InterestExpense
2000 USD
us-gaap Interest Expense
InterestExpense
3000 USD
us-gaap Increase Decrease In Employee Related Liabilities
IncreaseDecreaseInEmployeeRelatedLiabilities
1112000 USD
us-gaap Increase Decrease In Employee Related Liabilities
IncreaseDecreaseInEmployeeRelatedLiabilities
75000 USD
us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
87000 USD
us-gaap Net Cash Provided By Used In Operating Activities Continuing Operations
NetCashProvidedByUsedInOperatingActivitiesContinuingOperations
-10743000 USD
us-gaap Net Cash Provided By Used In Operating Activities Continuing Operations
NetCashProvidedByUsedInOperatingActivitiesContinuingOperations
-11461000 USD
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
14000 USD
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
40000 USD
us-gaap Net Cash Provided By Used In Investing Activities Continuing Operations
NetCashProvidedByUsedInInvestingActivitiesContinuingOperations
1036000 USD
us-gaap Net Cash Provided By Used In Investing Activities Continuing Operations
NetCashProvidedByUsedInInvestingActivitiesContinuingOperations
-40000 USD
us-gaap Proceeds From Issuance Of Preferred Stock And Preference Stock
ProceedsFromIssuanceOfPreferredStockAndPreferenceStock
8917000 USD
us-gaap Proceeds From Issuance Of Preferred Stock And Preference Stock
ProceedsFromIssuanceOfPreferredStockAndPreferenceStock
2378000 USD
us-gaap Repayments Of Long Term Debt
RepaymentsOfLongTermDebt
21000 USD
us-gaap Repayments Of Long Term Debt
RepaymentsOfLongTermDebt
6000 USD
us-gaap Net Cash Provided By Used In Financing Activities Continuing Operations
NetCashProvidedByUsedInFinancingActivitiesContinuingOperations
8911000 USD
us-gaap Net Cash Provided By Used In Financing Activities Continuing Operations
NetCashProvidedByUsedInFinancingActivitiesContinuingOperations
2357000 USD
us-gaap Net Cash Provided By Used In Continuing Operations
NetCashProvidedByUsedInContinuingOperations
-796000 USD
us-gaap Net Cash Provided By Used In Continuing Operations
NetCashProvidedByUsedInContinuingOperations
-9144000 USD
us-gaap Preferred Stock Accretion Of Redemption Discount
PreferredStockAccretionOfRedemptionDiscount
2891000 USD
us-gaap Preferred Stock Accretion Of Redemption Discount
PreferredStockAccretionOfRedemptionDiscount
2577000 USD
us-gaap Stock And Warrants Issued During Period Value Preferred Stock And Warrants
StockAndWarrantsIssuedDuringPeriodValuePreferredStockAndWarrants
-149000 USD
CY2013 us-gaap Operating Leases Rent Expense Net
OperatingLeasesRentExpenseNet
300000 USD
CY2014Q2 us-gaap Operating Leases Rent Expense Net
OperatingLeasesRentExpenseNet
600000 USD
us-gaap Operating Leases Rent Expense Net
OperatingLeasesRentExpenseNet
800000 USD
CY2014Q2 us-gaap Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent
5000 USD
us-gaap Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent
5000 USD
CY2014Q2 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-4633000 USD
CY2013Q2 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-4889000 USD
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-10628000 USD
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-10433000 USD
CY2014Q2 us-gaap Business Combination Bargain Purchase Gain Recognized Amount
BusinessCombinationBargainPurchaseGainRecognizedAmount
3634000 USD
us-gaap Increase Decrease In Other Current Assets
IncreaseDecreaseInOtherCurrentAssets
10000 USD
us-gaap Increase Decrease In Other Current Assets
IncreaseDecreaseInOtherCurrentAssets
-92000 USD
CY2014Q2 astm Operating Leases Leased Office Space Future Minimum Payments Remainder Of Fiscal Year
OperatingLeasesLeasedOfficeSpaceFutureMinimumPaymentsRemainderOfFiscalYear
1784000 USD
CY2014Q2 astm Operating Leases Leased Office Space Future Minimum Payments Due In Two Years
OperatingLeasesLeasedOfficeSpaceFutureMinimumPaymentsDueInTwoYears
4088000 USD
CY2014Q2 astm Operating Leases Leased Office Space Future Minimum Payments Due In Three Years
OperatingLeasesLeasedOfficeSpaceFutureMinimumPaymentsDueInThreeYears
4056000 USD
CY2014Q2 astm Operating Leases Leased Office Space Future Minimum Payments Due In Four Years
OperatingLeasesLeasedOfficeSpaceFutureMinimumPaymentsDueInFourYears
1196000 USD
CY2014Q2 astm Operating Leases Leased Office Space Future Minimum Payments Due In Five Years
OperatingLeasesLeasedOfficeSpaceFutureMinimumPaymentsDueInFiveYears
333000 USD
CY2014Q2 astm Operating Leases Leased Office Space Future Minimum Payments Due
OperatingLeasesLeasedOfficeSpaceFutureMinimumPaymentsDue
11457000 USD
CY2014Q2 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
4317000 USD
CY2013Q4 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
8000 USD
CY2014Q2 us-gaap Accrued Liabilities Current And Noncurrent
AccruedLiabilitiesCurrentAndNoncurrent
0 USD
CY2014Q2 astm Value Of Additional Common Shares Could Be Sold
ValueOfAdditionalCommonSharesCouldBeSold
9300000 USD
CY2014Q2 astm Common Stock Remaining Capacity
CommonStockRemainingCapacity
9300000 USD

Files In Submission

Name View Source Status
0001104659-14-060912-index-headers.html Edgar Link pending
0001104659-14-060912-index.html Edgar Link pending
0001104659-14-060912.txt Edgar Link pending
0001104659-14-060912-xbrl.zip Edgar Link pending
a14-14109_110q.htm Edgar Link pending
a14-14109_1ex31d1.htm Edgar Link pending
a14-14109_1ex31d2.htm Edgar Link pending
a14-14109_1ex32d1.htm Edgar Link pending
a14-14109_1ex32d2.htm Edgar Link pending
astm-20140630.xml Edgar Link completed
astm-20140630.xsd Edgar Link pending
astm-20140630_cal.xml Edgar Link unprocessable
astm-20140630_def.xml Edgar Link unprocessable
astm-20140630_lab.xml Edgar Link unprocessable
astm-20140630_pre.xml Edgar Link unprocessable
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xls Edgar Link pending
Financial_Report.xlsx Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R46.htm Edgar Link pending
R47.htm Edgar Link pending
R48.htm Edgar Link pending
R49.htm Edgar Link pending
R5.htm Edgar Link pending
R50.htm Edgar Link pending
R51.htm Edgar Link pending
R52.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending